Study of the Epidemiology of COVID-19 in Teachers and Education Workers in Elementary and Secondary Schools in Ontario
The objectives of this study are:
* To estimate the rate of previous exposure to COVID-19 as evidenced by the prevalence of anti-SARS-CoV-2 antibodies in teachers and education workers at enrolment (February or March, 2021);
* To identify workplace (e.g., level of student contact, school/class size, age of pupils, school-wide protective measures), community (e.g., rates of infection, outbreak level), household (e.g., number of housemates, housemates’ exposures, confirmed COVID-19 infections), and individual (e.g., age, health status, individual protective measures) risk and protective factors for COVID-19 in teachers and education workers;
* To determine the incidence of symptomatic COVID-19 infection in teachers and education workers between February or March 2021 and February or March 2022;
* To estimate the incidence of asymptomatic infection in teachers and education workers between February or March 2021 and February or March 2022 as measured by seroconversion to anti-SARS-CoV-2 antibodies;
* To describe the psychological impact of working during an outbreak of a novel respiratory virus;
* To describe the changes in anti-SARS-CoV-2 antibodies over a one-year follow-up period in participants who have detectable antibodies measured at baseline;
* To determine the percentage of teachers and education workers who intend to be vaccinated against COVID-19 (at baseline); and
* To determine the incidence of and factors associated with re-infection (exploratory objective).
Overview
- Acronym
- CCS-2
- Website
- CCS-2
- Investigators
-
- Contacts
-
General Design
- Study design
- Cross-sectional
- Start - End Year
- 2021 - 2022
- General Information on Follow Up (profile, frequency)
-
Participants who tested negative (Cohort A) or positive (Cohort B) for antibodies to SARS-CoV-2 at enrolment will be followed for 12 months: biweekly, every 13 weeks, prior to – and 30 days after – receipt of each COVID vaccine (as possible).
- Recruitment Target
-
- Individuals
- Number of Participants
- 7,000
- Number of Participants with Biological Samples
- 7,000
- Supplementary Information
-
The study is a cross-sectional study (Phase I) followed by two nested prospective cohort sub-studies (Phase II).
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
|
Supplementary Information
French: http://www.tibdn.ca/covid-19/education-fr
Timeline
Population
CCS-2 population
The population is composed of teachers and education workers (educational assistants, school office staff, custodians, librarians, early childhood educators), aged between 18-74 years old, in Ontario.
Selection Criteria
- Minimum age
-
18
- Maximum age
-
74
- Countries
-
- Canada
- Canadian Provinces
-
- Ontario
- Health Status
-
- Do not have a bleeding disorder, have not had chemotherapy in the past 4 weeks, and have not had a bilateral mastectomy
- Other Criteria
- Inclusion: employed in any capacity by an Ontario public school board or independent school; work, on average, at least 8 hours per week and can be available for at least the next 3 months after enrolment
Sources of Recruitment
- Specific Population
-
- Other specific population : Teachers and education workers
- Supplementary Information
-
Participants were recruited by advertising of the study to key partners membership, using a variety of media including inclusion in emails and updates and posting on their website and social media sites; promoting the study through stories about the study and interviews on radio, newspapers, and television, and posting on Facebook, Twitter, and LinkedIn.
Sample Size
- Number of Participants
- 7,000
- Number of Participants with Biological Samples
- 7,000
- Supplementary information about number of participants
-
Phase I: 7000 participants
Phase II Cohort A: 6650 participants
Phase II Cohort B: 350 participants
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | CCS-2 - Phase I Baseline |
|
2021 (January) | 2021 (February) | |
| 1 | CCS-2 - Phase II Follow-up 1 |
|
|
2021 (March) | 2021 (May) |
| 2 | CCS-2 - Phase II Follow-up 2 |
|
|
2021 (June) | 2021 (August) |
| 3 | CCS-2 - Phase II Follow-up 3 |
|
|
2021 (September) | 2021 (November) |
| 4 | CCS-2 - Phase II Follow-up 4 |
|
|
2021 (December) | 2022 (February) |
| 5 | CCS-2 - Phase II Vaccination |
|
|
2021 (June) | 2022 (March) |
| 6 | CCS-2 - Phase II 30-days post-vaccination |
|
|
2021 (June) | 2022 (March) |
| 7 | CCS-2 - Phase II Biweekly reports |
|
2021 (January) | 2022 (March) |
Participating Studies
| Acronym | Name | Study design | Countries |
|---|
Harmonization Initiatives Included
| Acronym | Name |
|---|
Datasets
| Name | Data Collection Events | Variables |
|---|
Areas of Information Collected
- Socio-demographic and economic characteristics
- Death
- Lifestyle and behaviours
- Physical measures and assessments
- Birth, pregnancy and reproductive health history
- Laboratory measures
- Perception of health, quality of life, development and functional limitations
- Cognition, personality and psychological measures and assessments
- Diseases
- Life events, life plans, beliefs and values
- Symptoms and signs
- Preschool, school and work life
- Medication and supplements
- Social environment and relationships
- Non-pharmacological interventions
- Physical environment
- Health and community care services utilization
- Administrative information
Variables Content Summary
Areas of Information Collected
No Areas of Information Collected
No Scales Collected
Areas of Information Collected per per Population and Data Collection Event
No Areas of Information Collected
No Scales Collected
Networks
| Acronym | Name | Harmonization Initiatives | Individual Studies |
|---|
Last Update: 2024-02-27T06:33:40.449